Skip to main content
NEKTAR THERAPEUTICS logo

NEKTAR THERAPEUTICS - Investor Relations & Filings

Listed
Ticker · NKTR ISIN · US6402681083 LEI · 5299005I24806IOIYE03 US Manufacturing
Open in API
Filings indexed 1,240 across all filing types
Latest filing 2026-02-10 Regulatory Filings
Country US United States of America
Listing US NKTR · 14 venues

About NEKTAR THERAPEUTICS

https://www.nektar.com/

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for autoimmune and inflammatory conditions. The company's research centers on modulating the immune system to resolve imbalances and restore homeostasis. By leveraging its expertise in immune pathways, Nektar aims to develop first-in-class, disease-modifying therapies that address the root causes of immune dysfunction. Its pipeline includes investigational candidates such as rezpegaldesleukin, a therapy designed to stimulate regulatory T cells for the treatment of conditions like severe alopecia areata.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 10, 2026. It provides an update on the company's cash and investments as of January 31, 2026, but does not contain comprehensive financial statements or detailed financial analysis. The document is relatively short (3,257 characters) and primarily serves as a regulatory announcement of a financial update rather than a full financial report. It does not fit the criteria for Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a certification or officer attestation. Given the nature of the filing and its content, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-02-10 English
424B5 Filing
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock and pre-funded warrants. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5) and references a registration statement filed with the SEC. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering, which fits the category of Capital/Financing Update (CAP). It is not an annual or quarterly report, audit report, earnings release, or any other category. The document length and content confirm it is a full prospectus supplement, not just an announcement or a brief summary.
2026-02-10 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-01-30 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text mentions a quiet period beginning January 27, 2026, related to data analysis from a Phase 2b study, and states that the next investor communication is expected in February 2026. There are no financial statements or detailed financial data included, only a notification about the quiet period and upcoming data disclosure. The document length is 4290 characters, which is relatively short and consistent with a current report rather than a full financial report. This type of filing is a regulatory announcement of a material event, not an annual or quarterly report, earnings release, or other detailed financial document. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2026-01-27 English
4 Filing
Director's Dealing
2026-01-22 English
4 Filing
Director's Dealing
2025-12-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.